Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» EXACT Sciences
EXACT Sciences
Medtech’s haves and have-nots
Medtech’s haves and have-nots
EP Vantage
earnings
devices
Medtech
Medtronic
EXACT Sciences
Thermo Fisher
Abbott Labs
Roche
Qiagen
JNJ
Zimmer Biomet
Smith & Nephew
Boston Scientific
Flag link:
Exact Sciences-Guardant rivalry in colorectal testing market heats up
Exact Sciences-Guardant rivalry in colorectal testing market heats up
Medtech Dive
EXACT Sciences
Guardant Health
diagnostics
colorectal cancer
Ashion Analytics
M&A
Flag link:
Exact Sciences Falls in After-Hours Trading on Q4 Results
Exact Sciences Falls in After-Hours Trading on Q4 Results
Motley Fool
EXACT Sciences
earnings
Flag link:
The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
Yahoo/Benzinga
earnings
FDA
G1 Therapeutics
trilaciclib
Zoetis
EXACT Sciences
Blueprint Medicines
Ironwood Pharmaceuticals
Flag link:
The top medtech deals of 2020 (and one that got away)
The top medtech deals of 2020 (and one that got away)
Medtech Dive
devices
Medtech
M&A
Teladoc
Livongo Health
Stryker
Wright Medical
Medtronic
EXACT Sciences
Philips
BioTelemetry
Illumina
Grail
Siemens
Varian
Flag link:
A month after Illumina's big Grail buyout, Exact Sciences scoops up liquid biopsy rival Thrive for a relative bargain
A month after Illumina's big Grail buyout, Exact Sciences scoops up liquid biopsy rival Thrive for a relative bargain
Endpoints
EXACT Sciences
M&A
Thrive Earlier Detection
liquid biopsy
diagnostics
Flag link:
Exact gatecrashes the liquid biopsy party
Exact gatecrashes the liquid biopsy party
EP Vantage
EXACT Sciences
liquid biopsy
diagnostics
pan-cancer assay
Flag link:
Exact Sciences Beats Q2 Estimates Despite a COVID-19 Drag
Exact Sciences Beats Q2 Estimates Despite a COVID-19 Drag
Motley Fool
EXACT Sciences
earnings
Flag link:
Exact Sciences Acquires 2 Cancer Diagnostic Companies
Exact Sciences Acquires 2 Cancer Diagnostic Companies
Motley Fool
EXACT Sciences
M&A
diagnostics
cancer
Paradigm Diagnostics
Viomics
Flag link:
Exact Sciences Should Benefit from Pfizer’s News Today
Exact Sciences Should Benefit from Pfizer’s News Today
Motley Fool
Pfizer
colorectal cancer
EXACT Sciences
FDA
Braftovi
Cologuard
Flag link:
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Adamis Pharmaceuticals
Redhill Biopharma
Amag Pharmaceuticals
Arqule
Agile Therapeutics
Agios Pharmaceuticals
Deciphera
Mirati Therapeutics
Sutro BioPharma
Merck
Pfizer
Amgen
EXACT Sciences
Bristol-Myers Squibb
Celgene
Oyster Point Pharma
Flag link:
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
Yahoo/Zacks.com
EXACT Sciences
Cologuard
diagnostics
colorectal cancer
Flag link:
How $2.8B Genomic Health deal catapults Exact beyond Cologuard
How $2.8B Genomic Health deal catapults Exact beyond Cologuard
BioCentury
EXACT Sciences
M&A
Genomic Health
Cologuard
cancer
diagnostics
Flag link:
Exact Sciences Buying Genomic Health in $2.8B Cancer Diagnostics Deal
Exact Sciences Buying Genomic Health in $2.8B Cancer Diagnostics Deal
Xconomy
EXACT Sciences
M&A
Genomic Health
diagostics
Flag link:
How Exact Sciences Reinvented Itself
How Exact Sciences Reinvented Itself
Medical Devices and Diagnostics Industry
diagnostics
EXACT Sciences
Kevin Conroy
Flag link:
Why Exact Sciences Stock Sank Today
Why Exact Sciences Stock Sank Today
Motley Fool
EXACT Sciences
Affordable Care Act
Cologuard
Flag link:
As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround
As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround
Xconomy
EXACT Sciences
Kevin Conroy
diagnostics
colorectal cancer
Cologuard
Flag link:
Exact Sciences Hit a Home Run in Q4. Here's Why Sales Could Soon Soar Even More
Exact Sciences Hit a Home Run in Q4. Here's Why Sales Could Soon Soar Even More
Yahoo/Motley Fool
EXACT Sciences
earnings
Cologuard
Flag link:
4 Things Exact Sciences Investors Should Know About 23andMe's New Cancer Test
4 Things Exact Sciences Investors Should Know About 23andMe's New Cancer Test
Motley Fool
23andMe
EXACT Sciences
diagnostics
colorectal cancer
Cologuard
Flag link:
Behind the Exact Sciences/Pfizer Cologuard co-promotion deal
Behind the Exact Sciences/Pfizer Cologuard co-promotion deal
Medical Marketing and Media
Pfizer
EXACT Sciences
Cologuard
diagnostics
colon cancer
Flag link:
Pages
1
2
3
4
next ›
last »